Showing results (251-260 of 291) with videos related to

Sort By:
Pageof 30
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2022
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studyM Maio, P A Ascierto, L Manzyuk, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trialC Suarez, C Rojas, S J Shin, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agentsM A Seefeld, W H Miller, K A Newlander, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI)D A Heerding, G Chan, W E DeWolf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonistK W Ward, L M Azzarano, W E Bondinell, et al.
ESMO Open|December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trialT K Choueiri, T M Kuzel, S S Tykodi, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumorsM D Hellmann, T-W Kim, C B Lee, et al.
Pageof 30